FDA Approves New Pegfilgrastim Biosimilar for Cancer Treatment

The FDA has granted approval for a new pegfilgrastim biosimilar, which is designed to reduce infection risk in cancer patients undergoing treatment. This approval marks a significant milestone for Accord BioPharma, as it becomes the only company in the U.S. to offer two pegfilgrastim biosimilars. This development could enhance treatment options and accessibility for patients.